SEC Form 4 · accession 0001610717-26-000414
10x Genomics, Inc. · TXG
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Adam Taich
Officer — Chief Financial Officer
Period of report
Sep 9, 2026
Accepted (ET)
Sep 11, 2026 · 4:47 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001770787
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Common StockF2 | Sep 9, 2026 | S | 1,206 | $63.6774 | D | 361,526 | D | |
| Class A Common StockF3 | Sep 9, 2026 | S | 31,428 | $64.3097 | D | 330,098 | D | |
| Class A Common StockF4 | Sep 9, 2026 | S | 13,754 | $65.2574 | D | 316,344 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on June 10, 2026.
- F2This transaction was executed in multiple trades at prices ranging from $63.67 to $63.83, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- F3This transaction was executed in multiple trades at prices ranging from $64.01 to $64.87, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- F4This transaction was executed in multiple trades at prices ranging from $64.88 to $65.875, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.